Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept
Rhea-AI Filing Summary
Vor Biopharma Inc. entered into a securities purchase agreement with entities affiliated with TCGX for a private placement of 5,338,078 common shares at $14.05 per share, for gross proceeds of about $75.0 million. The closing is expected on or about March 30, 2026, subject to customary conditions.
After closing, Vor expects to have 54,185,582 common shares outstanding. The company plans to use the net proceeds to advance its clinical pipeline, including telitacicept programs, and for general corporate purposes. No placement agent was used. Vor also granted investors registration rights and will file a Form S-3 to register the resale of the new shares.
Positive
- $75.0 million gross proceeds from the private placement provide substantial new capital to fund clinical development and corporate needs.
- No placement agent engaged for the transaction, which may reduce external fees compared with brokered financings.
Negative
- Issuance of 5,338,078 new common shares in the private placement increases the total share count, creating equity dilution for existing stockholders.
Insights
$75M private placement strengthens Vor Bio’s cash position but adds new equity.
Vor Biopharma has arranged a private placement with TCGX affiliates for 5,338,078 common shares at $14.05, generating about $75.0 million in gross proceeds. The deal is expected to close around March 30, 2026, with no placement agent involved.
This is a straightforward cash-in equity financing, increasing the company’s share count to 54,185,582 after closing. The proceeds are earmarked to advance telitacicept and other clinical programs, plus general corporate purposes, which is typical for a clinical-stage biotech funding its pipeline.
A registration rights agreement requires Vor to file a Form S-3 to register the investors’ resale of the new shares, with liquidated damages if timing milestones are missed. Future disclosures in periodic reports will help clarify how quickly the new capital is deployed into trials and business development.
8-K Event Classification
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
On March 26, 2026, Vor Biopharma Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with TCGX (the “Investors”) pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares (the “Shares”) of the Company’s common stock, at a price per Share of $14.05, for gross proceeds of approximately $75.0 million (the “Private Placement”). The Purchase Agreement contains customary representations and warranties of the Company, on the one hand, and the Investors, on the other hand, and customary conditions to closing. The closing of the Private Placement is expected to occur on March 30, 2026, subject to customary closing conditions. Upon the closing of the Private Placement, the Company will have 54,185,582 shares of common stock outstanding. The Company intends to use the net proceeds from the Private Placement to advance development of its clinical pipeline and for general corporate purposes.
In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated March 26, 2026 (the “Registration Rights Agreement”), with the Investors. Pursuant to the terms of the Registration Rights Agreement, the Company is obligated to prepare and file with the Securities and Exchange Commission (“SEC”) a registration statement on Form S-3 (the “Registration Statement”) to register for resale the Shares within 30 days of the closing date of the Private Placement and to use its reasonable best efforts to have the Registration Statement declared effective as soon as possible, but no later than 60 days after the closing date of the Private Placement, subject to extension under the terms of the Registration Rights Agreement. The Registration Rights Agreement provides for liquidated damages payable to the Investors if the Company fails to meet certain filing or effectiveness deadlines, subject to specified caps. The Registration Rights Agreement includes customary provisions regarding payment of fees and expenses and indemnification.
The foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Purchase Agreement and the form of Registration Rights Agreement, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.
The representations, warranties and covenants contained in the Purchase Agreement and the Registration Rights Agreement were made solely for the benefit of the parties to the Purchase Agreement and the Registration Rights Agreement and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Purchase Agreement and the Registration Rights Agreement are incorporated herein by reference only to provide investors with information regarding the terms of the Purchase Agreement and the Registration Rights Agreement and not to provide investors with any other factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.
Item 3.02 Unregistered Sales of Equity Securities.
The disclosures set forth in Item 1.01 above regarding the Private Placement are incorporated into this Item 3.02.
The Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act. Each Investor has represented that it is a “qualified institutional buyer,” as defined in Rule 144A under the Securities Act or an institutional “accredited investor” (as defined in Rule 501(a) under the Securities Act), that it is purchasing the Shares solely for such Investor’s own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and that such Investor has no present intention of selling, granting any participation in, or otherwise distributing the Shares in violation of the Securities Act. The sale of the Shares did not involve a public offering and was made without general solicitation or general advertising.
Item 7.01 Regulation FD Disclosure.
On March 27, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
Description |
10.1 |
Form of Securities Purchase Agreement. |
10.2 |
Form of Registration Rights Agreement. |
99.1 |
Press Release, dated March 27, 2026. |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “plan,” “potential,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this Current Report on Form 8-K include the Company’s expectations regarding the closing of the Private Placement and the use of proceeds therefrom, the anticipated filing of a registration statement to cover resales of the Shares, and other statements that are not historical fact. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of clinical trials and clinical development of the Company’s product candidates; availability and timing of results from clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; uncertainties regarding regulatory approvals to conduct trials or to market products; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent annual or quarterly report and in other reports it has filed or may file with the SEC. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Vor Biopharma Inc. |
|
|
|
|
Date: |
March 27, 2026 |
By: |
/s/ Jean-Paul Kress |
|
|
|
Jean-Paul Kress |
Vor Bio Announces $75 Million Private Placement with TCGX
BOSTON, Mass., March 27, 2026 (GLOBE NEWSWIRE) – Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 5,338,078 shares of its common stock at a price of $14.05 per share in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $75 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions.
The financing is led by new investor TCGX.
"BAFF/APRIL inhibition represents one of the next major waves of innovation in autoimmune disease, and telitacicept is at the forefront of the field. With compelling Phase 3 data across multiple indications and tens of thousands of patients treated in China, we believe telitacicept's clinical profile and robust safety data to date provide a unique opportunity to bring a differentiated, potentially disease-modifying therapy to patients globally,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. “This financing enables us to accelerate our efforts in generalized myasthenia gravis and, importantly, advance primary Sjögren’s disease as a key next frontier – two large, multi-billion-dollar opportunities where significant unmet need remains and where we believe telitacicept can meaningfully change the treatment paradigm. We are well positioned to deliver on our commitment to maximize the impact of telitacicept for patients and drive long-term value for shareholders.”
“Our investment reflects the conviction we have in the Vor Bio team and the disruptive potential of telitacicept," said Cariad Chester, Managing Partner at TCGX. “With its differentiated efficacy profile, we believe telitacicept has the potential to become a foundational therapy for multiple B-cell mediated diseases. We are excited to support the pivotal development program of telitacicept and help build Vor Bio into a global leader in treating autoimmune diseases.”
Vor Bio intends to use the net proceeds from the private placement to advance the clinical development of telitacicept, including the ongoing global Phase 3 clinical trials for myasthenia gravis and primary Sjögren's disease, business development, and for working capital and general corporate purposes.
The offer and sale of the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with entering into the securities purchase agreement, Vor Bio and the investors entered into a registration rights agreement pursuant to which Vor Bio has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
About TCGX
TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCGX invests in pioneering healthcare companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCGX has investment teams in San Francisco, Palo Alto, and New York City. For more information, please visit: www.tcgcrossover.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the private placement, including expected proceeds, expected use of proceeds and expected closing of the private placement; the potential of telitacicept and the BAFF/APRIL inhibition, Vor Bio’s opportunity to bring a differentiated, potentially disease-modifying therapy to patients globally, telitacicept’s potential to meaningfully change the treatment paradigm and become a foundational therapy for multiple B-cell mediated diseases, our market opportunities, and other statements that are not historical fact.
Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including market conditions and failure of customary closing conditions. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. The results of the clinical trial described in this press release is based on information reported by RemeGen; Vor Bio has not independently verified this data.
Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
FAQ
What did Vor Biopharma (VOR) announce in this 8-K filing?
Vor Biopharma announced a private placement financing with entities affiliated with TCGX, selling 5,338,078 common shares at $14.05 per share for about $75.0 million in gross proceeds. The transaction is expected to close around March 30, 2026, subject to customary conditions.
How will Vor Biopharma (VOR) use the $75 million in proceeds?
Vor Biopharma intends to use the net proceeds from the approximately $75.0 million private placement to advance development of its clinical pipeline, including telitacicept programs, and for working capital and general corporate purposes, supporting its broader autoimmune disease treatment strategy.
Did Vor Biopharma (VOR) use a placement agent for this financing?
No, Vor Biopharma did not engage a placement agent in connection with the private placement. The company directly entered into a securities purchase agreement with entities affiliated with TCGX to sell 5,338,078 common shares for gross proceeds of about $75.0 million.
What registration rights did Vor Biopharma grant to investors in this deal?
Vor Biopharma agreed to file a Form S-3 registration statement to register the resale of the private placement shares within 30 days after closing. The company must use reasonable best efforts to have it declared effective within 60 days, with liquidated damages if deadlines are missed.
Who is leading Vor Biopharma’s $75 million private placement?
The private placement is led by new investor TCGX, a healthcare investment firm. Entities affiliated with TCGX agreed to purchase 5,338,078 shares of Vor Biopharma common stock at $14.05 per share, providing gross proceeds of approximately $75.0 million to the company.
Filing Exhibits & Attachments
4 documentsPress Releases
Agreements & Contracts
